共 39 条
- [32] Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study (vol 14, pg 5441, 2020) DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 515 - 516
- [33] Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy PULMONARY PHARMACOLOGY & THERAPEUTICS, 2014, 27 (02) : 190 - 196
- [36] Effectiveness and Safety of AVESSA™, (Fixed Dose Combination of Formoterol 6 mcg and Fluticasone Propionate 250 mcg) Dry Powder Inhaler (DPI), in Management of "Partly Controlled & Uncontrolled" Asthma - A Real World Study in India. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
- [37] Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients PRIMARY CARE RESPIRATORY JOURNAL, 2013, 22 (04): : 439 - 448
- [38] THE POTENTIAL TO IMPROVE INHALATION TECHNIQUE IN PATIENTS WITH ASTHMA OR COPD BY SWITCHING FROM SYMBICORT® TURBUHALER® (BUDESONIDE plus FORMOTEROL) TO DUORESP® SPIROMAX® : ESTIMATED IMPACT ON THE NUMBER AND COST OF UNSCHEDULED HEALTHCARE EVENTS IN POLAND VALUE IN HEALTH, 2016, 19 (07) : A688 - A688